Thus, a humanized monoclonal antibody against VEGF has recently been approved by the FDA based upon its improved response rates and retardation of tumor progression, although these effects have been modest and temporary, and sometimes with severe adverse side-effects [37]. The gene discussed is VEGFA; the disease is neoplasm.